S&P 500   3,690.77 (+0.66%)
DOW   30,131.88 (+0.54%)
QQQ   305.43 (+0.38%)
AAPL   122.19 (-0.61%)
MSFT   214.19 (-0.02%)
FB   280.32 (-0.54%)
GOOGL   1,824.78 (+0.16%)
AMZN   3,174.63 (-0.38%)
TSLA   594.55 (+0.20%)
NVDA   540.13 (+0.80%)
BABA   267.33 (+0.16%)
CGC   28.99 (+1.26%)
GE   10.72 (+1.13%)
MU   73.39 (+4.99%)
AMD   93.53 (+1.32%)
T   29.52 (+0.99%)
NIO   43.40 (-4.30%)
F   9.39 (+1.95%)
ACB   11.67 (+3.83%)
BA   233.16 (-1.70%)
NFLX   499.14 (+0.33%)
GILD   61.27 (+0.67%)
DIS   153.49 (+0.16%)
S&P 500   3,690.77 (+0.66%)
DOW   30,131.88 (+0.54%)
QQQ   305.43 (+0.38%)
AAPL   122.19 (-0.61%)
MSFT   214.19 (-0.02%)
FB   280.32 (-0.54%)
GOOGL   1,824.78 (+0.16%)
AMZN   3,174.63 (-0.38%)
TSLA   594.55 (+0.20%)
NVDA   540.13 (+0.80%)
BABA   267.33 (+0.16%)
CGC   28.99 (+1.26%)
GE   10.72 (+1.13%)
MU   73.39 (+4.99%)
AMD   93.53 (+1.32%)
T   29.52 (+0.99%)
NIO   43.40 (-4.30%)
F   9.39 (+1.95%)
ACB   11.67 (+3.83%)
BA   233.16 (-1.70%)
NFLX   499.14 (+0.33%)
GILD   61.27 (+0.67%)
DIS   153.49 (+0.16%)
S&P 500   3,690.77 (+0.66%)
DOW   30,131.88 (+0.54%)
QQQ   305.43 (+0.38%)
AAPL   122.19 (-0.61%)
MSFT   214.19 (-0.02%)
FB   280.32 (-0.54%)
GOOGL   1,824.78 (+0.16%)
AMZN   3,174.63 (-0.38%)
TSLA   594.55 (+0.20%)
NVDA   540.13 (+0.80%)
BABA   267.33 (+0.16%)
CGC   28.99 (+1.26%)
GE   10.72 (+1.13%)
MU   73.39 (+4.99%)
AMD   93.53 (+1.32%)
T   29.52 (+0.99%)
NIO   43.40 (-4.30%)
F   9.39 (+1.95%)
ACB   11.67 (+3.83%)
BA   233.16 (-1.70%)
NFLX   499.14 (+0.33%)
GILD   61.27 (+0.67%)
DIS   153.49 (+0.16%)
S&P 500   3,690.77 (+0.66%)
DOW   30,131.88 (+0.54%)
QQQ   305.43 (+0.38%)
AAPL   122.19 (-0.61%)
MSFT   214.19 (-0.02%)
FB   280.32 (-0.54%)
GOOGL   1,824.78 (+0.16%)
AMZN   3,174.63 (-0.38%)
TSLA   594.55 (+0.20%)
NVDA   540.13 (+0.80%)
BABA   267.33 (+0.16%)
CGC   28.99 (+1.26%)
GE   10.72 (+1.13%)
MU   73.39 (+4.99%)
AMD   93.53 (+1.32%)
T   29.52 (+0.99%)
NIO   43.40 (-4.30%)
F   9.39 (+1.95%)
ACB   11.67 (+3.83%)
BA   233.16 (-1.70%)
NFLX   499.14 (+0.33%)
GILD   61.27 (+0.67%)
DIS   153.49 (+0.16%)
Log in
ASX:BNO

Bionomics Limited (BNO.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.04
MA: A$0.04
A$0.04
52-Week Range N/A
Volume386,458 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, the company offers ionX, an integrated platform of genomics discoveries and technologies. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+61-8-83546100
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.19 million
Book ValueA$0.02 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableOptionable

Receive BNO News and Ratings via Email

Sign-up to receive the latest news and ratings for BNO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Bionomics Limited (BNO.AX) (ASX:BNO) Frequently Asked Questions

What stocks does MarketBeat like better than Bionomics Limited (BNO.AX)?

Wall Street analysts have given Bionomics Limited (BNO.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bionomics Limited (BNO.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Bionomics Limited (BNO.AX)'s earnings last quarter?

Bionomics Limited (BNO.AX) (ASX:BNO) issued its earnings results on Friday, February, 15th. The company reported ($0.02) EPS for the quarter.
View Bionomics Limited (BNO.AX)'s earnings history
.

Who are some of Bionomics Limited (BNO.AX)'s key competitors?

What other stocks do shareholders of Bionomics Limited (BNO.AX) own?

Who are Bionomics Limited (BNO.AX)'s key executives?

Bionomics Limited (BNO.AX)'s management team includes the following people:
  • Dr. Errol B. De Souza, Exec. Chairman (Age 67, Pay $363.28k)
  • Mr. Adrian Hinton, Acting Chief Financial Officer
  • Mr. Jack Moschakis B.E., BEc, DipLaw(BAB), GDipBA, FCIS, Legal Counsel & Company Sec.
  • Prof. Paul Rolan, Consultant Chief Medical Officer of Clinical Neuroscience

What is Bionomics Limited (BNO.AX)'s stock symbol?

Bionomics Limited (BNO.AX) trades on the ASX under the ticker symbol "BNO."

How big of a company is Bionomics Limited (BNO.AX)?

Bionomics Limited (BNO.AX) has a market capitalization of $0.00 and generates $3.19 million in revenue each year.

What is Bionomics Limited (BNO.AX)'s official website?

The official website for Bionomics Limited (BNO.AX) is www.bionomics.com.au.

How can I contact Bionomics Limited (BNO.AX)?

Bionomics Limited (BNO.AX)'s mailing address is 31 Dalgleish St, THEBARTON, SA 5031, Australia. The company can be reached via phone at +61-8-83546100.

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.